Superworth

Wave Life Sciences price to sales ratio WVE

Market value divided by revenue over the last twelve months, since 2017.

Today, Nov 2, 2026
9.8×
9-year median
20.3×
Against its 9-year history
24th
percentile: 0 is its lowest day, 100 its highest
9-year range
1.8× to 197×
Peer median
1.6×

Wave Life Sciences' price to sales ratio is 9.8× as of Nov 2, 2026.

That is below its 9-year median of 20.3×, lower than on 76% of days in the last 9 years.

Over that time it ranged from 1.8× in May 2022 to 197× in Aug 2017.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far9.8×9.8×10.0×
202514.6×14.6×18.6×
202417.8×4.5×21.1×
20235.9×5.1×121×
2022146×1.8×146×
202113.7×13.7×43.2×
202029.4×14.2×56.9×
201931.5×30.4×109×
201899.9×87.7×181×
2017197×197×197×

Against its peers

Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Wave Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.